Risks
3 risks
Risk Intelligence
Rising finance costs
View Risks →Fredun Pharmaceuticals Ltd — Q4 FY26
Fredun Pharmaceuticals delivered a strong Q4 FY26 with revenue of ₹213 crore (+27% YoY), EBITDA of ₹29.1 crore (+67% YoY), and PAT of ₹11.1 crore (+56% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fredun Pharmaceuticals delivered a strong Q4 FY26 with revenue of ₹213 crore (+27% YoY), EBITDA of ₹29.1 crore (+67% YoY), and PAT of ₹11.1 crore (+56% YoY). EBITDA margin expanded 326 bps to 13.67%, driven by a favorable mix shift toward higher-margin new-age businesses (pet care, mobility, nutraceuticals) and operating leverage in the vintage business. Management guided for 25-30% top-line growth in FY27, with PAT margins expected to reach 10-12% over the next few years as demographic expansion for new products matures. Key growth drivers include the upcoming hormone/anti-aging product launch and the pet care platform Vagger.in. Risks include rising finance costs due to debt-funded growth and potential margin pressure from raw material inflation, though management believes these are manageable.
फ्रेडुन फार्मास्यूटिकल्स ने वित्त वर्ष 2026 की चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई 213 करोड़ रुपये रही, जो पिछले साल से 27% ज्यादा है। कमाई में से खर्चे निकालने के बाद बचा मुनाफा (EBITDA) 29.1 करोड़ रुपये (+67%) और शुद्ध मुनाफा (PAT) 11.1 करोड़ रुपये (+56%) रहा। मुनाफे की दर (EBITDA margin) 13.67% हो गई, जो पिछले साल से 3.26% ज्यादा है। इसकी वजह कंपनी का ज्यादा मुनाफे वाले नए कारोबारों (पालतू जानवरों की देखभाल, मोबिलिटी, न्यूट्रास्युटिकल्स) पर ध्यान देना है। कंपनी को अगले वित्त वर्ष में 25-30% कमाई बढ़ने की उम्मीद है और अगले कुछ सालों में शुद्ध मुनाफे की दर 10-12% तक पहुंच सकती है। नए उत्पादों जैसे हार्मोन/एंटी-एजिंग और पेट केयर प्लेटफॉर्म वैगर.इन से ग्रोथ मिलेगी। हालांकि, कर्ज लेकर बढ़ने से ब्याज खर्च बढ़ सकता है और कच्चे माल की कीमतें बढ़ने से मुनाफे पर दबाव पड़ सकता है, लेकिन कंपनी इसे संभालने में सक्षम है।
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Order Book
₹320-330 crore
N/A
Orders in hand for next 6-7 months, providing revenue visibility.
Pet Care Revenue
₹42-43 crore
+40-50% YoY
New-age pet care business growing rapidly from a small base.
Mobility Revenue
₹29-30 crore
+55-60% YoY
Mobility division growing at a CAGR of 55-60%.
Product Registrations Pipeline
1,000+
N/A
Over 1,000 registrations in pipeline to drive vintage business growth.
What Changed vs Last Quarter
NEW
FY27 top-line growth of 25-30%
Management expects overall revenue growth of 25-30% in FY27, driven by new-age businesses and steady vintage growth.
NEW
PAT margin target of 10-12% in a few years
Management targets PAT margin of 10-12% within the next few years as new-age businesses scale and demographics saturate.
NEW
Mobility division to reach ₹100 crore run-rate in 2-2.5 years
Mobility business expected to achieve ₹100 crore run-rate within 2-2.5 calendar years, and ₹250-300 crore in 5-7 years.
NEW
Vagger.in platform launch in July 2026
Pet care e-commerce platform Vagger.in to soft-launch in mid-June and full launch in first week of July 2026.
DROPPED
Vintage business to grow 12-18% YoY for 5-7 years
Legacy business (exports, institutional, third-party) expected to grow 12-18% annually driven by 1,300-1,400 product registrations.
DROPPED
New-age business to grow 20-25% YoY
Dermatics, pet care, and nutritionals expected to grow 20-25% annually; 51% of revenue by FY29-30.
DROPPED
Further margin expansion in 6-7 quarters
Operating leverage from high-margin new-age brands will drive profit growth over next 6-7 quarters.
DROPPED
No immediate fund requirement for 12-18 months
Current funds and internal cash flows sufficient; no equity raise planned in near term.
NEW RISK
Rising finance costs
Finance costs are elevated due to debt-funded growth; management acknowledges the need to improve cost ratios.
NEW RISK
Raw material price inflation
Geopolitical tensions have increased raw material costs; management mitigates with buffer stock but margins could be pressured if sustained.
NEW RISK
Working capital strain from rapid growth
Fast organic growth may stretch working capital; management claims improvement but inventory remains high at ₹270 crore.
RISK GONE
Finance cost increase from rapid expansion
Finance costs rose due to working capital needs and new machinery loans; may pressure near-term profitability.
RISK GONE
Seasonality and margin volatility in Q4
Q4 typically has higher revenue but lower margins due to year-end discounts and schemes.
RISK GONE
Execution risk in new-age business scale-up
New-age brands require state-wise launches and penetration; operational leverage may take longer than expected.
Fast read
Guidance and risk preview
Management expects overall revenue growth of 25-30% in FY27, driven by new-age businesses and steady vintage growth.
Finance costs are elevated due to debt-funded growth; management acknowledges the need to improve cost ratios.
View Risks →